DBV Technologies : Half-Year Report on the DBV Technologies Liquidity Contract with Natixis

AMFREGULATED INFORMATION

Montrouge, France, January 16, 2018

Half-Year Report on the DBV TechnologiesLiquidity Contract with Natixis

Under the liquidity contract between DBV TECHNOLOGIES and NATIXIS, the following assets appeared on the liquidity account as of December 29, 2017:

• - 4,939 DBV TECHNOLOGIES shares;

• -€1,332,828.26

As of June 30, 2017, the following assets appeared on the liquidity account:

• - 4,697 DBV TECHNOLOGIES shares;

• -€1,281,514.28

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applicationsin immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of deliveringbiologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the careof food allergic patients, for whom there are no approved treatments. DBV's food allergies programs includeongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:www.dbv-technologies.com

DBV Investor Relations ContactSara Blum Sherman

Director, Investor Relations [phone]

DBV Media Contact

Roberta Di Giorgio

Head, Corporate Communications [phone]